• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV-1 发夹前中间体抑制剂的疗效不依赖中和作用。

HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.

机构信息

Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.

Sarafan ChEM-H, Stanford University, Stanford, CA 94305.

出版信息

Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2215792120. doi: 10.1073/pnas.2215792120. Epub 2023 Feb 16.

DOI:10.1073/pnas.2215792120
PMID:36795752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9974412/
Abstract

HIV-1 strains are categorized into one of three neutralization tiers based on the relative ease by which they are neutralized by plasma from HIV-1-infected donors not on antiretroviral therapy; tier-1 strains are particularly sensitive to neutralization while tier-2 and tier-3 strains are increasingly difficult to neutralize. Most broadly neutralizing antibodies (bnAbs) previously described target the native prefusion conformation of HIV-1 Envelope (Env), but the relevance of the tiered categories for inhibitors targeting another Env conformation, the prehairpin intermediate, is not well understood. Here, we show that two inhibitors targeting distinct highly conserved regions of the prehairpin intermediate have strikingly consistent neutralization potencies (within ~100-fold for a given inhibitor) against strains in all three neutralization tiers of HIV-1; in contrast, best-in-class bnAbs targeting diverse Env epitopes vary by more than 10,000-fold in potency against these strains. Our results indicate that antisera-based HIV-1 neutralization tiers are not relevant for inhibitors targeting the prehairpin intermediate and highlight the potential for therapies and vaccine efforts targeting this conformation.

摘要

HIV-1 毒株根据其在未接受抗逆转录病毒治疗的 HIV-1 感染者血浆中的相对易中和性,分为三个中和等级之一;1 级毒株特别容易被中和,而 2 级和 3 级毒株则越来越难以中和。以前描述的大多数广谱中和抗体(bnAbs)针对 HIV-1 包膜(Env)的天然前融合构象,但针对另一种 Env 构象——发夹前中间体的抑制剂的分层类别相关性尚不清楚。在这里,我们表明,两种针对发夹前中间体不同高度保守区域的抑制剂对 HIV-1 的所有三个中和等级的毒株具有惊人一致的中和效力(对于给定的抑制剂,在~100 倍以内);相比之下,针对不同 Env 表位的最佳类别 bnAbs 对这些毒株的效力差异超过 10,000 倍。我们的结果表明,基于抗血清的 HIV-1 中和等级与针对发夹前中间体的抑制剂无关,并强调了针对这种构象的疗法和疫苗努力的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/9974412/c9737cf11c2a/pnas.2215792120fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/9974412/8c8d66eba828/pnas.2215792120fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/9974412/dfe44b0ea99c/pnas.2215792120fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/9974412/c9737cf11c2a/pnas.2215792120fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/9974412/8c8d66eba828/pnas.2215792120fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/9974412/dfe44b0ea99c/pnas.2215792120fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/9974412/c9737cf11c2a/pnas.2215792120fig03.jpg

相似文献

1
HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.HIV-1 发夹前中间体抑制剂的疗效不依赖中和作用。
Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2215792120. doi: 10.1073/pnas.2215792120. Epub 2023 Feb 16.
2
A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.一种针对 HIV-1 gp41 N-七肽重复序列的 D5 单克隆抗体衍生物,具有广泛的 Tier-2 中和活性。
J Virol. 2021 Jul 12;95(15):e0235020. doi: 10.1128/JVI.02350-20.
3
Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.通过引导HIV-1包膜糖蛋白进入扰动敏感的非天然状态的因子,在多种二级分离株中诱导出类似一级的表型。
J Virol. 2017 Jul 12;91(15). doi: 10.1128/JVI.00174-17. Print 2017 Aug 1.
4
Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.针对具有传播奠基者Env的HIV-1细胞间传播的广谱中和抗体的效力降低及中和不完全
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02425-16. Print 2017 May 1.
5
A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.婴儿来源的 HIV-1 包膜糖蛋白中的一个罕见突变改变了二聚体间的稳定性,并影响了针对三聚体顶部的广谱中和抗体的敏感性。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00814-20.
6
HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.非人灵长类动物免疫接种引发的HIV-1交叉反应性原发性病毒中和抗体反应
J Virol. 2017 Oct 13;91(21). doi: 10.1128/JVI.00910-17. Print 2017 Nov 1.
7
A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.一种模拟共受体的肽增强了 V3 糖基抗体的效力。
J Virol. 2019 Feb 19;93(5). doi: 10.1128/JVI.01653-18. Print 2019 Mar 1.
8
Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.通过对包膜免疫原进行策略性选择实现针对2级HIV-1病毒的强效自体中和抗体反应。
J Immunol. 2016 Apr 1;196(7):3064-78. doi: 10.4049/jimmunol.1500527. Epub 2016 Mar 4.
9
Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.MW965包膜蛋白中调节原发性HIV-1分离株中和表型及构象屏蔽潜力的新型结构决定因素的鉴定。
J Virol. 2018 Feb 12;92(5). doi: 10.1128/JVI.01779-17. Print 2018 Mar 1.
10
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.广泛中和性抗HIV-1抗体对在外周血单核细胞中产生的B亚型临床分离株的中和活性
J Virol. 2018 Feb 12;92(5). doi: 10.1128/JVI.01883-17. Print 2018 Mar 1.

引用本文的文献

1
Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat.利用机器学习提高靶向gp41 N-七肽重复序列的HIV-1抗体的中和效力。
ACS Chem Biol. 2025 Jul 18;20(7):1470-1480. doi: 10.1021/acschembio.5c00035. Epub 2025 Jun 20.
2
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning.一种通过双特异性抗体介导的预定位作用具有增强的HIV-1中和能力的广谱抗体。
Nat Commun. 2025 May 18;16(1):4617. doi: 10.1038/s41467-025-60035-6.
3
Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1.

本文引用的文献

1
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.用于预防 HIV-1 获得性感染的抗体介导中和效价生物标志物。
Nat Med. 2022 Sep;28(9):1924-1932. doi: 10.1038/s41591-022-01953-6. Epub 2022 Aug 22.
2
Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.通过 HIV-1 包膜蛋白Env 顶点的相互作用调节 gp41 膜近端外部区的表位暴露。
PLoS Pathog. 2022 May 18;18(5):e1010531. doi: 10.1371/journal.ppat.1010531. eCollection 2022 May.
3
A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.
超越聚糖障碍:非同源配体和蛋白质模拟方法引发针对 HIV-1 的广谱中和抗体。
J Biomed Sci. 2024 Aug 21;31(1):83. doi: 10.1186/s12929-024-01073-y.
一种针对 HIV-1 gp41 N-七肽重复序列的 D5 单克隆抗体衍生物,具有广泛的 Tier-2 中和活性。
J Virol. 2021 Jul 12;95(15):e0235020. doi: 10.1128/JVI.02350-20.
4
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.两项预防 HIV-1 感染的中和抗体随机临床试验
N Engl J Med. 2021 Mar 18;384(11):1003-1014. doi: 10.1056/NEJMoa2031738.
5
Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.针对 SARS-CoV-2 受体结合域的中和抗体,该抗体源自一个原始的人源抗体文库。
Protein Sci. 2021 Apr;30(4):716-727. doi: 10.1002/pro.4044. Epub 2021 Feb 24.
6
A new lease on life for an HIV-neutralizing antibody class and vaccine target.一类HIV中和抗体及疫苗靶点迎来了新的生机。
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7). doi: 10.1073/pnas.2026390118.
7
The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat.高亲和力免疫球蛋白受体 FcγRI 通过针对 gp41 N-七肽重复序列的抗体增强 HIV-1 中和作用。
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3). doi: 10.1073/pnas.2018027118.
8
Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate.利用融合抑制剂捕获发夹前中间体来可视化 HIV-1 与靶细胞融合的电子断层扫描。
Elife. 2020 Jul 22;9:e58411. doi: 10.7554/eLife.58411.
9
Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.广谱中和单克隆抗体用于人类免疫缺陷病毒预防的临床试验:综述。
J Infect Dis. 2021 Feb 13;223(3):370-380. doi: 10.1093/infdis/jiaa377.
10
Asymmetric opening of HIV-1 Env bound to CD4 and a coreceptor-mimicking antibody.HIV-1 Env 与 CD4 和类共受体抗体结合后的不对称开口。
Nat Struct Mol Biol. 2019 Dec;26(12):1167-1175. doi: 10.1038/s41594-019-0344-5. Epub 2019 Dec 2.